



03CD

Docket No. ORT1273

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Andrew L. Darrow et al  
Serial No. : 09/607,745 Art Unit:  
Filed : June 30, 2000 Examiner:  
For : DNA ENCODING HUMAN SERINE PROTEASE D-G

#8  
Bq  
3/12/03

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed  
to: Assistant Commissioner For Patents, Washington, D.C. 20231 on

October 18, 2000

(Date of Deposit)

John W. Wallen III

(Name of applicant, assignee, or Registered Representative)

(Signature)

October 18, 2000

(Date of Signature)

Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37  
C.F.R. §§1.97-1.98, information relating to the above-identified  
application is hereby disclosed. Inclusion of information in  
this statement is not to be construed as an admission that this  
information is material as that term is defined in 37 C.F.R.  
§1.56(b).

☒ In accordance with §1.97(b), since this Information  
Disclosure Statement is being filed either within three months  
of the filing date of the above-identified application, within  
three months of the date of entry into the national stage of the  
above identified application as set forth in §1.491, or before

the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Certification in Accordance with §1.97(e) is set forth below; or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$240.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

- ☐ Certification in Accordance with §1.97(e) is set forth below; or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$240.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Certification in Accordance with §1.97(e) as set forth below and the fee of \$130.00 as set forth in §1.17(i)(1).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ In accordance with §1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. §120 have been made in the instant application:

☐ Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. , filed .

☒ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.


☐ The relevance of those listed references which are not in the English language is as follows:

☒ There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT1273/JWW. This form is submitted in triplicate.




Respectfully submitted,

  
John W. Wallen III  
Reg. No. 35,403  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(858) 784-3239  
DATED: October 18, 2000

Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>	Docket No.	Serial No.
	ORT1273	09/607,745
	Applicant Andrew L. Darrow et al.	
	Filing Date	Group Art Unit
	June 30, 2000	



## U.S. PATENT DOCUMENTS

Exam'r Init.	Document No.	Date	Name	Class	Sub Class	File Date

## FOREIGN PATENT DOCUMENTS

Exam'r Init.	Document No.	Date	Country	Class	Sub Class	Translate (select one) Yes No	
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER REFERENCES (include author, title, date, pertinent pages, etc.)

		Davie, E.W.; Fujikawa, K.; Kisiel, W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 30, 10363-70, 1991.
		Ishii, K.; Hein, L.; Kobilka, B.; Coughlin, S.R. Kinetics of thrombin receptor cleavage on intact cells. Relation to signaling. J. Biol. Chem. 268, 9780-6, 1993.
		Leytus, S.P.; Loeb, K.R.; Hagen, F.S.; Kurachi, K.; Davie, E.W. A novel trypsin-like serine protease (hepsin) with a putative transmembrane domain expressed by human liver and hepatoma cells. Biochemistry 27, 1067-74, 1988.
		Paoloni-Giacobino, A.; Chen, H.; Peitsch, M.C.; Rossier, C. Antonarakis, S.E. Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3. Genomics 44, 309-320, 1997.
		Proud, D.; Kaplan, A.P. Kinin formation: mechanisms and role in inflammatory disorders. Annu. Rev. Immunol. 6, 49-83, 1988.
		Reid, K.B.M., Porter, R.R. The proteolytic activation systems of complement. Annual Review of Biochemistry 50, 433-464, 1981.

Examiner:	Date Considered
Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	